Skip to main content

Drug Interactions between neratinib and venetoclax

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

venetoclax neratinib

Applies to: venetoclax and neratinib

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with P-glycoprotein inhibitors (P-gp) may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter. Administration of venetoclax with a single dose of rifampin, a P-gp inhibitor when given acutely, increased the peak plasma concentration (Cmax) and systemic exposure (AUC) of venetoclax by 106% and 78%, respectively. Increased venetoclax exposure may potentiate the risk of tumor lysis syndrome, particularly at initiation of therapy and during the dosage ramp-up phase, as well as other adverse effects such as diarrhea, nausea, vomiting, neutropenia, anemia, and thrombocytopenia.

MANAGEMENT: In patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), concomitant use of P-gp inhibitors with venetoclax at its steady daily dosage (after the ramp-up dosage titration phase) should generally be avoided. Some authorities advise that the concomitant use of P-gp inhibitors with venetoclax should also be avoided at initiation and during the dose titration phase in patients with CLL/SLL. However, if coadministration is required, the manufacturer recommends the venetoclax dosage be reduced by at least 50% of the original dose for patients with CLL/SLL as well as patients with acute myeloid leukemia (AML) All patients, regardless of indication, should be monitored closely for signs and symptoms of venetoclax-related adverse effects/toxicities and the dosage modified accordingly. In addition, the dosage used prior to initiating the P-gp inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor.

Drug and food interactions

Major

venetoclax food

Applies to: venetoclax

Food helps to increase the absorption of venetoclax. You should take each dose of venetoclax with a meal and water at approximately the same time each day. Do not consume grapefruit, grapefruit juice, Seville oranges, or starfruit during treatment with venetoclax. Doing so can significantly increase blood levels and effects of the medication. This may increase your risk of developing tumor lysis syndrome, a serious condition that is caused by the rapid breakdown of cancer cells and that can lead to kidney failure and even death. In addition, you may be more likely to experience other side effects such as nausea; vomiting; diarrhea; fatigue; and impaired bone marrow function resulting in low numbers of different types of blood cells, which can increase the risk of anemia, bleeding problems, and infections. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Major

neratinib food

Applies to: neratinib

Grapefruit juice can increase the blood levels of neratinib. This may increase the risk and/or severity of side effects such as diarrhea, nausea, vomiting, abdominal pain, mouth sores, loss of appetite, and liver problems. You should avoid the consumption of grapefruit and grapefruit juice during treatment with neratinib. Be sure to take the medication with food at the same time everyday to maintain consistent blood levels and effects. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer